FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

Print this page BOSTON–(BUSINESS WIRE)–Jun. 21, 2019– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane… Read More »

FTC approves UnitedHealth Group $4.3 billion acquisition of DaVita, with conditions

The Federal Trade Commission has approved UnitedHealth Group’s $ 4.3 billion acquisition of DaVita Medical Group, with conditions. UnitedHealth Group and DaVita have agreed to divest DaVita Medical Group’s provider organization in the Las Vegas Area, known as HealthCare Partners of Nevada, to Intermountain Healthcare in Utah, no later than 40 days after acquisition. The… Read More »

The profound cynicism of Jack Dorsey and other abortion-promoting CEOs

Earlier this month, a coalition of CEOs launched an ad campaign voicing their opposition to new state-level laws that seek to protect unborn children and their mothers from abortion at various stages of pregnancy. In a campaign pulled together by Planned Parenthood and other abortion advocacy groups, executives at 180 companies signed their name to… Read More »